Our regulatory affairs department has highly qualified professionals who always keep their technical knowledge abreast of the latest developments in the pharma field. The team keeps a close watch on the Patent Situation and suggests a product mix in tune with our overall business strategy. As the world pharma markets expect about USD 40billion worth of molecules going off patent and entering the generic regime, our Core Management Team in constant coordination with the Regulatory Cell monitors these molecules and then adopts suitable course of action in terms of our product mix for the Finished Doses and APIs as well.